Applied Genetic Technologies Corp

NASDAQ:AGTC   3:59:58 PM EDT
4.69
+0.02 (+0.43%)
Products, Regulatory, Other Pre-Announcement

AGTC Reports Additional Positive Data From Its Phase 1/2 Clinical Trial In Patients With X-Linked Retinitis Pigmentosa

Published: 11/11/2020 12:14 GMT
Applied Genetic Technologies Corp (AGTC) - Agtc Reports Additional Positive Data From Its Phase 1/2 Clinical Trial in Patients With X-linked Retinitis Pigmentosa.
Applied Genetic Technologies - Durable Improvements Observed in Visual Sensitivity & Visual Acuity Over Wide Dose-range With Favorable Safety Profile.
Applied Genetic Technologies - Plans to Initiate Enrollment in Phase 1/2 Expansion Trial (skyline) in 4q 2020 and Phase 2/3 Trial (vista) in 1q 2021.
Applied Genetic Technologies Corp - Expects to Provide Results From 6-month Interim Analysis of Vista Trial in 3q 2022.